Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
Indivior Pharmaceuticals, Inc INDV
$36.59
▼ -0.79%
($-0.29)
Open
$36.74
Prev Close
$36.88
Day Range
$36.08 – $37.05
52W Range
$22.56 – $42.81
Market Cap
$4.32B
P/E (TTM)
12.13
Beta
0.50
EPS (TTM)
$2.78
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-06-12 |
| Shares Out. | 121,000,000 |
| Website | indivior.com/ ↗ |
| Phone | 18043791090 |
| Employees | 838 |
| Revenue | $343.0M |
| Gross Profit | $293.0M |
| Net Income | $122.0M |
| Free Cash Flow | -$111.0M |
| Total Assets | $1.23B |
| Total Liabilities | $1.44B |
| Equity | -$208.0M |
About Indivior Pharmaceuticals, Inc
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
Indivior Pharmaceuticals, Inc is a publicly traded company under the ticker symbol INDV on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)